|
|
Podium Session I - 10:45 - 11:45 |
Cardiovascular Disease I |
CV1 |
POST-AMI DRUG THERAPY PERSISTENCE AND RISK OF REINFARCTION IN A MEDICAID POPULATION |
|
Shaya FT, Gu A |
|
University of Maryland School of Pharmacy, Baltimore, MD, USA |
| |
|
CV2 |
COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN FROM A CANADIAN HEALTH CARE PERSPECTIVE |
|
Costa-Scharplatz M1, Beamer B2, Frial T2, Gandhi SK3 |
|
1AstraZeneca, Södertälje, Sweden, 2AstraZeneca, Mississauga, ON, Canada, 3AstraZeneca, LP, Wilmington, DE, USA |
| |
|
CV3 |
DO DIFFERENCES IN DOSE IMPACT ADHERENCE TO SINGLE-PILL AMLODIPINE/ATORVASTATIN VERSUS 2-PILL AMLODIPINE AND ATORVASTATIN? |
|
Tang SSK1, Patel BV2, Leslie RS2, Thiebaud P2, Nichol MB3, Solomon HA1, Trainer JB1, Foody JM4 |
|
1Pfizer Inc, New York, NY, USA, 2MedImpact Healthcare Systems, Inc, San Diego, CA, USA, 3University of Southern California, Los Angeles, CA, USA, 4Yale University, New Haven, CT, USA |
| |
|
CV4 |
BENEFIT/RISK OF IRBESARTAN/HYDROCHLOROTHIAZIDE AS FIRST-LINE TREATMENT OF SEVERE HYPERTENSION |
|
Lapuerta P1, Gomez A2, Franklin S3 |
|
1Bristol-Myers Squibb, Princeton, NJ, USA, 2Bristol-Myers Squibb, Hopewell, NJ, USA, 3University of California at Irvine, Los Angeles, CA, USA |
|
|
Economics of Diabetes |
| |
|
ED1 |
COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS IN A GERMAN SETTING. A MODELING EVALUATION BASED UPON RESULTS FROM A META-ANALYSIS. |
|
Kotchie R1, Scheijbeler H1, Aagren M2, Nielsen S2, Valentine WJ3, Goodall G3 |
|
1IMS Health, London, UK, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, Basel, Switzerland |
|
|
ED2 |
LONG-TERM COST-UTILITY ANALYSIS OF INSULIN ASPART (NOVORAPID®) VERSUS HUMAN SOLUBLE INSULIN IN TYPE 2 DIABETES PATIENTS IN THE GERMAN SETTING |
|
Goodall G1, Valentine WJ1, Townsend C2, Kotchie R3, Nielsen S2, Erny-Albrecht K1 |
|
1IMS Health, Basel, Switzerland, 2Novo Nordisk A/S, Virum, Denmark, 3IMS Health, London, UK |
| |
|
ED3 |
DIFFERENCES IN HEALTH RELATED RESOURCE USE IN THE 6 MONTHS PRIOR TO AND AFTER INSULIN INITIATION IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY AND UK: DATA FROM THE INSTIGATE STUDY |
|
Timlin L1, Tynan A1, Simpson A1, Jones S2, Liebl A3 |
|
1Eli Lilly and Company Limited, Surrey, UK, 2The James Cook University Hospital, Middlesborough, UK, 3Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany |
| |
|
ED4 |
THE RELATIVE COST EFFECTIVENESS OF SWITCHING TO INSULIN GLARGINE VERSUS NPH INSULIN IN INSULIN NAIVE AND NON INSULIN NAIVE TYPE 2 DIABETES PATIENTS USING UK REAL LIFE DATA |
|
McEwan P1, Mehin N2, Tetlow AP3, Sharplin P3 |
|
1Cardiff University, Cardiff, South Glamorgan, UK, 2sanofi-aventis, Paris, France, 3Cardiff Research Consortium, Cardiff, South Glamorgan, UK |
|
|
Methods & Concepts |
| |
|
MC1 |
ASSESSING THE GENERALISABILITY OF COST EVALUATION RESULTS USING THE EUCLIDEAN METRIC AND PRINCIPAL COMPONENTS ANALYSIS: LESSON FROM A HIGH-COST INNOVATION IN ONCOLOGY |
|
Perrier L1, Pommier P1, Carrère MO2, Sylvestre Baron P3 |
|
1Léon Bérard Cancer Centre, Lyon, France, 2University of Lyon, Lyon, France, 3University of Lyon, Ecully, France |
| |
|
MC2 |
BAYESIAN MODELING OF RESOURCE USE ALONGSIDE MULTINATIONAL RANDOMISED CLINICAL TRIALS |
|
Gauthier A1, Manca A2, Anton SF3, Dewberry H4 |
|
1i3 Innovus, Uxbridge, Middlesex, UK, 2University of York, York, UK, 3Boehringer-Ingelheim, Ridgefield, CT, USA, 4Boehringer Ingelheim Limited, Bracknell, Berkshire, UK |
| |
|
MC3 |
THE DEVELOPMENT OF AN INCREMENTAL WILLINGNESS TO PAY CURVE DERIVED FROM A DISCRETE CHOICE EXPERIMENT |
|
Regier DA1, Marra CA2, Ryan M1 |
|
1University of Aberdeen, Aberdeen, Scotland, UK, 2University of British Columbia, Vancouver, BC, Canada |
| |
|
MC4 |
COMPARISON OF THREE INSTRUMENTS ASSESSING THE QUALITY OF ECONOMIC EVALUATIONS |
|
Gerkens S, Crott R, Beguin C, Closon MC, Horsmans Y |
|
Université Catholique de Louvain, Brussels, Belgium |
|
|
Patient Reported Outcomes I |
| |
|
PR1 |
RECOMPUTING VALUES FOR EQ-5D IN ACCORDANCE WITH NICE APPRAISAL GUIDANCE |
|
Kind P |
|
University of York, York, UK |
| |
|
PR2 |
NON-PERSISTENT USE OF ORAL ANTIDIABETIC DRUGS LEADS TO 20% DECREASED CHANCE OF HBA1C GOAL-ATTAINMENT IN DAILY CLINICAL PRACTICE |
|
Koerselman J1, van der Bij S1, Erkens JA1, Kessabi S2, Groot MT3, Penning-van Beest FJ1, Herings RM1 |
|
1PHARMO Institute, Utrecht, Utrecht, The Netherlands, 2Novartis Pharma AG, Basel, Switzerland, 3Novartis Pharma B.V, Arnhem, The Netherlands |
| |
|
PR3 |
PATIENTS', PARENTS', AND PHYSICIANS' RISK-BENEFIT TRADE-OFF PREFERENCES FOR CROHN'S DISEASE TREATMENTS |
|
Johnson FR1, Ozdemir S1, Mansfield C1, Hauber AB1, Hass SL2, Siegel CA3, Sands BE4, Miller DW2 |
|
1RTI International, RTP, NC, USA, 2Elan Pharmaceuticals Inc, San Diego, CA, USA, 3Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, 4Massachusetts General Hospital, Boston, MA, USA |
| |
|
PR4 |
BACK PAIN IN GERMANY: ARE THERE DIFFERENCES CONCERNING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS TREATED ACCORDING TO GUIDELINES, GUIDELINE INDEPENDENT AND PATIENT SELF-TREATMENT? |
|
Breitscheidel L1, Stridde E2, Kreyenberg K1, Benter U1, Eichmann F1 |
|
1Kendle GmbH, Munich, Germany, 2Pfizer Pharma GmbH, Karlsruhe, Germany |
|
|
Podium Session II - 12:00 - 13:00 |
Cancer |
| |
|
CN1 |
USING THE FACT-NEUROTOXICITY TO EVALUATE QUALITY OF LIFE IN CANCER PATIENTS FROM ACROSS THE GLOBE |
|
Eremenco S, Du H, Arnold B, Herzberg T, Cella D |
|
Evanston Northwestern Healthcare, Evanston, IL, USA |
| |
|
CN2 |
DEVELOPMENT AND VALIDATION OF OPTIMALLY WEIGHTED MEASURES OF GLOBAL HEALTH-RELATED QUALITY OF LIFE (QOL) AND UTILITY BASED ON A CANCER-SPECIFIC QOL INSTRUMENT |
|
Grimison PS, Simes RJ, Stockler MR |
|
NHMRC Clincial Trials Centre, University of Sydney, CAMPERDOWN, NSW, Australia |
| |
|
CN3 |
EFFECTIVENESS OF EPOETIN ALPHA VERSUS DARBEPOETIN IN CHEMOTHERAPY-INDUCED ANAEMIA IN THE GERMAN SETTING |
|
Ezzat N1, Brüggenjürgen B2, Willich SN2 |
|
1Alpha Care GmbH, Celle, Germany, 2Charite University Medical Center, Berlin, Germany |
| |
|
CN4 |
COST-EFFECTIVENESS OF PEGYLATED LIPISOMAL DOXORUBICIN VS. CONVENTIONAL DOXORUBICIN IN AVOIDANCE OF CARDIOTOXICITY FOR METASTATIC BREAST CANCER IN THE FIRST TREATMENT YEAR |
|
Singer ME1, Sandor DW2, Reardon G3 |
|
1Case Western Reserve University School of Medicine, Cleveland, OH, USA, 2Touro University College of Medicine, Hackensack, NJ, USA, 3Informagenics, LLC, Worthington, OH, USA |
|
|
Economic Studies I |
ES1 |
INCREMENTAL DIFFERENCES IN RESOURCE UTILIZATION AND COSTS OF TREATING PERSONS INFECTED WITH HIV IN A LOW SOCIOECONOMIC NEIGHBORHOOD |
|
Johnston KM1, Levy A1, Lai C2, Briggs A3, Kerr T2, Montaner JS2, Tyndall M1 |
|
1University of British Columbia, Vancouver, BC, Canada, 2British Columbia Centre for Excellence in HIV/AIDS Research, Vancouver, BC, Canada, 3University of Glasgow, Glasgow, UK |
| |
|
ES2/
PMH44
|
COSTS AND OUTCOMES OF ATYPICAL ANTIPSYCHOTICS FOR THE TREATMENT OF ACUTE SCHIZOPHRENIA |
|
Leeuwenkamp O1, Morlock R2, Bell CF3, Brogan A4, Mauskopf J4 |
|
1NV Organon, Molenstraat, Oss, The Netherlands, 2Pfizer Inc, Ann Arbor, MI, USA, 3GlaxoSmithKline, Memphis, TN, USA, 4RTI Health Solutions, Research Triangle Park, NC, USA |
| |
|
ES3 |
COST-EFFECTIVENESS OF FIRST EYE CATARACT SURGERY IN ELDERLY WOMEN: A RANDOMISED CONTROLLED TRIAL |
|
Sach TH1, Foss AJ2, Gregson RM2, Zaman A2, Osborn F2, Masud T2, Harwood RH2 |
|
1University of Nottingham, Nottingham, UK, 2Nottingham University Hospitals NHS Trust, Nottingham, UK
|
| |
|
ES4/PSU2 |
THE RELATIVE COST-EFFECTIVENESS OF THE FENTANYL HCL PATIENT-ACTIVATED TRANSDERMAL SYSTEM (ITS) IN ACUTE POST-OPERATIVE PAIN MANAGEMENT (POPM) IN GREECE |
|
Yfantopoulos I1, Papanicolaou S2, Papagianopoulou V1, Van Bellinghen LA3, Annemans L4 |
|
1University of Athens, Athens, Greece, 2Janssen-Cilag Pharmaceutical SACI, Athens, Greece, 3IMS HEOR, Brussels, Belgium, 4Ghent University, Ghent, Belgium |
|
|
Patient Reported Outcomes II |
| |
|
PR5 |
VALIDATION OF POMS QUESTIONNAIRE IN POSTMENOPAUSAL WOMEN |
|
Yu H1, Wyrwich K2, Bobula J1 |
|
1Wyeth Research, Collegeville, PA, USA, 2Saint Louis University, St. Louis, MO, USA |
| |
|
PR6 |
PATIENT CHARACTERISTICS IMPACTING QUALITY OF LIFE (EQ-5D) OF FEMALES WITH STRESS URINARY INCONTINENCE SYMPTOMS |
|
Tincello D1, Sculpher M2, Tunn R3, Quail D4, Timlin L4, Manning M5 |
|
1University of Leicester, Leicester, UK, 2University of York, York, UK, 3St Hedwig Hospitals, Berlin, Germany, 4Eli Lilly and Company Limited, Surrey, UK, 5Lilly Deutschland, BadHomburg, Germany |
| |
|
PR7 |
PATIENT'S PREFERENCES FOR OSTEOPOROSIS DRUG TREATMENT: A DISCRETE CHOICE EXPERIMENT |
|
De Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Pols HAP, Koes BW, Steyerberg EW |
|
Erasmus MC, Rotterdam, The Netherlands |
| |
|
PR8 |
EVALUATION OF IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE USING ORAL MESALAZINE ALONE OR IN COMBINATION WITH A MESALAZINE ENEMA IN ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMISED CONTROLLED TRIAL |
|
Nielsen SK1, Currie CJ2, Connolly MP1, Bhatt A1 |
|
1Ferring International Center, Saint-Prex, Switzerland, 2Cardiff University, Cardiff, UK |
|
|
Surgery |
SU1 |
COST-EFFECTIVENESS OF CYCLOOXYGENASE-2 INHIBITOR PARECOXIB COMPARED TO OPIOIDS AFTER NONCARDIAC SURGERY IN THE UK |
|
Remák E1, Muszbek N2, Manson SC3, Zlateva G4, Chen C4 |
|
1United Biosource Corporation, Budapest, Hungary, 2UnitedBiosource Corporation, London, UK, 3United BioSource Corporation, London, UK, 4Pfizer Inc, New York, NY, USA |
| |
|
SU2 |
MICRO-COSTING OF SURGICAL PROCEDURES RELATED TO INTRACEREBRAL HAEMORRHAGE IN A UK HEALTH CARE SETTING |
|
Manson SC1, De Cock E2, Jenkins AJ3, Twena N4 |
|
1United BioSource Corporation, London, UK, 2United BioSource Corporation, Barcelona, Spain, 3Newcastle General Hospital, Newcastle upon Tyne, UK, 4Novo Nordisk Ltd, Crawley, West Sussex, UK |
| |
|
SU3 |
NINE YEAR FOLLOW UP OF BIRMINGHAM HIP RESURFACING IN CONTEXT OF SURVIVAL AND COMPLICATIONS. |
|
Aulakh TS, Robinson EV, Richardson JB |
|
RJAH Orthopaedic Hospital, Oswestry, Shropshire, UK |
| |
|
SU4 |
THE COST-EFFECTIVENESS OF TITANIUM CAGE VERSUS FEMORAL RING ALLOGRAFT IN CIRCUMFERENTIAL LUMBAR FUSION: A RANDOMISED CONTROLLED TRIAL |
|
Sach TH1, Steele NA2, Hegarty J2, Soegaard R3, Freeman BJ2 |
|
1University of Nottingham, Nottingham, UK, 2Nottingham University Hospitals NHS Trust, Nottingham, UK, 3University of Aarhus, Aarhus, Denmark |
|
|
Podium Session III - 14:30 - 15:30 |
Diabetes |
| |
|
DB1 |
IMPACT OF ROSIGLITAZONE THERAPY ON THE LIPID PROFILE AND LIPID-LOWERING TREATMENT IN TYPE 2 DIABETES PATIENTS |
|
Suh DC1, Huang J1, Nocea G2, Yin D3, Krishnarajah G3 |
|
1Rutgers University, Piscataway, NJ, USA, 2MSD Spain, Madrid, Spain, 3Merck & Co., Inc, Whitehouse Station, NJ, USA |
| |
|
DB2 |
COMPARING BRITISH AND GERMAN DIABETES GUIDANCE WITH RESPECT TO LONGTERM OUTCOMES AND ASSOCIATED COSTS: RESULTS FROM THE EAGLE DIABETES SIMULATION MODEL |
|
Mueller E1, Huppertz E2, Stridde E3 |
|
1Analytica International, Loerrach, Germany, 2Consultant HE&RO, Niedererbach, Germany, 3Pfizer Pharma GmbH, Karlsruhe, Germany |
| |
|
DB3 |
CLINICAL AND PATIENT REPORTED OUTCOMES OVER THE FIRST 6 MONTHS OF INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES IN GERMANY AND UK: DATA FROM THE INSTIGATE STUDY |
|
Timlin L1, Tynan A1, Simpson A1, Liebl A2, Jones S3 |
|
1Eli Lilly and Company Limited, Surrey, UK, 2Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany, 3The James Cook University Hospital, Middlesborough, UK |
| |
|
DB4 |
TREATMENT ADHERENCE AND BARRIERS TO ADHERENCE ARE ASSOCIATED WITH GLYCEMIC CONTROL AND EXPERIENCE OF HYPOGLYCEMIA AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS (T2DM) ON ORAL ANTI-HYPERGLYCEMIC AGENTS (OHA) IN EUROPE |
|
Alvarez-Guisasola F1, Martin Castillo F2, Krishnarajah G3, Lyu R4, Mavros P4, Yin D4 |
|
1Centro de Salud La Calzada II, Gijón, Spain, 2Hospital General de Móstoles, Madrid, Spain, 3Merck & Co, Whitehouse Station, NJ, USA, 4Merck & Co., Inc, Whitehouse Station, NJ, USA |
|
|
Economics of Cancer |
EC1 |
RESOURCE USE AND COST OF DIAGNOSTIC WORKUP OF WOMEN WITH SUSPECTED BREAST CANCER |
|
Lee DW1, Stang PE2, Goldberg GA3, Haberman M4 |
|
1GE Healthcare, Waukesha, WI, USA, 2Independent Consultant, Blue Bell, PA, USA, 3i3 Innovus, Santa Monica, CA, USA, 4Thomson Medstat, Washington, DC, USA |
| |
|
EC2 |
AN ECONOMIC EVALUATION OF DASATINIB AS A TREATMENT FOR CHRONIC PHASE CHRONIC MYELOID LEUKAEMIA IN SCOTLAND |
|
Taylor MJ1, Minda K2, Cerri KH3, Davis C4, Kan HJ5, Ray S6 |
|
1University of York, York, UK, 2Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK, 3Bristol-Myers Squibb International Corporation, Braine l'Alleud, Braine l'Alleud, Belgium, 4Bristol-Myers Squibb, Wallingford, CT, USA, 5Bristol Myers Squibb, Wallingford, CT, USA, 6Bristol-Myers Squibb Pharmaceuticals, Wallingford, CT, USA |
| |
|
EC3 |
COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING |
|
Perrocheau G1, Ducreux M2, Hebbar M3, Ychou M4, Lledo G5, Conroy T6, Faroux R7, Douillard JY8, Pacull A9 |
|
1Centre René Gauducheau, Saint-Herblain, France, 2Institut Gustave Roussy, Villejuif, France, 3CHU, Lille, France, 4Centre Val d’Aurelle, Montpellier, France, 5Clinique Saint-Jean, Lyon, France, 6Centre Alexis Vautrin – Centre regional de Lutte contre le Cancer, Vandoeuvre les Nancy, France, 7Centre Hospitalier Départemental – Les Oudairies, La Roche sur Yon, France, 8Centre René Gauducheau, Nantes, France, 9Roche, Neuilly-sur-Seine, France |
| |
|
EC4 |
COST-EFFECTIVENESS AND COST-UTILITY OF RITUXIMAB MAINTENANCE THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA IN FRENCH SETTING |
|
Pacull A1, Coudray-Omnes C1, Brice P2, Deconinck E3, Le Pen C4, Miadi-Fargier H5 |
|
1Roche, Neuilly-Sur-Seine, France, 2Saint-Louis Hospital, Paris, France, 3INSERM U-645 Université de Franche-Comté CHU Jean Minjoz IFR 133, Besançon, France, 4Dauphine University, Paris, France, 5AREMIS - aegisnet, Neuilly sur Seine, France |
|
|
Health Care Use & Policy Studies |
HP1 |
HEALTH SYSTEM CORRELATES OF RECEIPT OF RADIATION AFTER BREAST CONSERVING SURGERY IN LOW-INCOME MEDICAID-ENROLLED WOMEN |
|
Anderson RT1, Balkrishnan R2 |
|
1Wake Forest University School of Medicine, Winston Salem, NC, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA |
| |
|
HP2 |
ASSOCIATIONS BETWEEN NEGATIVE SYMPTOMS, SERVICE USE, AND COSTS FOR PATIENTS WITH SCHIZOPHRENIA IN FIVE EUROPEAN COUNTRIES |
|
Leeuwenkamp O1, Knapp M2, McCrone P3 |
|
1NV Organon, Molenstraat, Oss, The Netherlands, 2London School of Economics, London, UK, 3King's College London, London, UK |
| |
|
HP3 |
ASSESSING THE IMPACT OF A NATIONAL DRUG BENEFIT PROGRAM ON THE USE OF GENERIC DRUGS AND DIFFERENT THERAPEUTIC CLASSES |
|
Zhang JX1, Yin W1, Sun SX2, Lee KY2, Meltzer DO1, Alexander GC1 |
|
1University of Chicago, Chicago, IL, USA, 2Walgreens Health Services, Deerfield, IL, USA |
| |
|
HP4 |
PROMOTING A DRUG'S HEALTH ECONOMIC ADVANTAGES IN MEDICAL JOURNAL ADVERTISING IN THE U.S.: A REVIEW OF 3,500 ADS FROM 1990-2006 |
|
Neumann PJ, Palmer JA, Timm AR |
|
Tufts-New England Medical Center, Boston, MA, USA |
|
|
Musculoskeletal Disease |
MD1 |
IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES |
|
Tang B1, Rahman MI1, Stephenson JJ2, Quimbo RA2, Thompson HC1, Naim A1, Dabbous O1 |
|
1Centocor, Inc, Horsham, PA, USA, 2HealthCore Inc, Wilmington, DE, USA |
| |
|
MD2 |
ECONOMIC CONSEQUENCES OF PROVIDING RITUXIMAB AS A TREATMENT ALTERNATIVE FOR RHEUMATOID ARTHRITIS IN THE NETHERLANDS |
|
Pompen M1, Diamantopoulos A2, Kievit W3, Moers R4, Kielhorn A5 |
|
1Roche Netherland BV, Woerden, The Netherlands, 2IMS Health, London, UK, 3Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 4Roche Nederland BV, Woerden, The Netherlands, 5F. Hoffmann-La Roche AG, Basel, Switzerland |
| |
|
MD3 |
CHANGES IN BODYWEIGHT AND ASSOCIATED DOSING REQUIREMENTS FOR RHEUMATOID ARTHRITIS PATIENTS RECEIVING INFLIXIMAB - RESULTS FROM ANALYSIS OF THE BRITISH SOCETY FOR RHEUMATOLOGY'S BIOLOGICS REGISTER (BSRBR) |
|
Gibbons CJ, Morris J, Abhyankar B |
|
Schering-Plough, Welwyn Garden City, UK |
| |
|
MD4 |
COST-EFFECTIVENESS OF BONE DENSITOMETRY SCREENING COMBINED WITH ALENDRONATE THERAPY FOR THOSE WHO HAVE OSTEOPOROSIS |
|
Hiligsmann M, Bruyère O, Ethgen O, Reginster JY |
|
University of Liège, Liège, Belgium |
|
|
Podium Session IV - 15:45 - 16:45 |
Cardiovascular Disease II |
CV5 |
FONDAPARINUX (FOND) VERSUS ENOXAPARIN (ENOX) FOR PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLIC EVENTS (VTE) IN PATIENTS UNDERGOING MAJOR ORTHOPEDIC SURGERY OF THE LOWER LIMBS (MOSLL) IN GERMANY: ECONOMIC EVALUATION FROM THE HOSPITAL PERSPECTIVE |
|
Schaedlich P1, Briswalter S2, Brecht J3 |
|
1Informed, Itzehoe, Germany, 2GlaxoSmithKline, Munich, Germany, 3Informed, Ingolstadt, Germany |
| |
|
CV6 |
SIROLIMUS-ELUTING VERSUS BARE-METAL CORONARY STENTS: 18-MONTH CLINICAL AND ECONOMIC OUTCOMES OF A CONTROLLED STUDY FOR THE REDUCTION OF CORONARY RESTENOSIS |
|
McBride D, Brüggenjürgen B, Roll S, Willich SN |
|
Charité University Medical Center, Berlin, Germany |
| |
|
CV7 |
COMPARISON OF THE COST-EFFECTIVENESS OF SEROLIMUS-ELUTING VERSUS BARE-METAL STENTS IN RELATION TO PATIENT CORONARY ARTERY DISEASE STATUS |
|
Brüggenjürgen B, McBride D, Roll S, Reinhold T, Willich SN |
|
Charité University Medical Center, Berlin, Germany |
| |
|
CV8 |
THE COST-EFFECTIVENESS (COST-UTILITY) OF EPROSARTAN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISEASE IN BELGIUM, GERMANY, SPAIN, UK, AND SWEDEN |
|
Schwander B1, Lindgren P2, Gradl B3 |
|
1Analytica International, Loerrach, Germany, 2I3 innovus, Stockholm, Sweden, 3Solvay Pharmaceuticals GmbH, Hannover, Germany |
|
|
Economic Studies II |
ES5 |
DOES ARTHROSCOPIC ACROMIOPLASTY PROVIDE ANY ADDITIONAL VALUE IN THE TREATMENT OF SHOULDER IMPINGEMENT SYNDROME? A TWO-YEAR RANDOMIZED CONTROLLED TRIAL
|
|
Ketola S1, Lehtinen J2, Arnala I1, Nissinen M1, Westenius H1, Aronen P3, Sintonen H3, Konttinen Y3, Malmivaara A4, Rousi T1
|
|
1Kanta-Häme Central Hospital, Hameenlinna, Finland, 2Tampere University, Tampere, Finland, 3University of Helsinki, Helsinki, Finland, 4Finnish Office for Health Care Technology Assessment, Helsinki, Finland |
| |
|
ES6 |
COST COMPARISON BETWEEN HAEMODIALYSIS AND PERITONEAL DIALYSIS IN NORWAY FOR PATIENTS WHO CAN USE EITHER TREATMENT MODALITY |
|
Nyhus K, Kristensen FKO, Merméjean P, Sverre JM |
|
PharmEcon, Asker, Akershus, Norway |
| |
|
ES7 |
ASSESSMENT OF LONG-RUN ECONOMIC BENEFITS ASSOCIATED WITH IN-VITRO FERTILIZATION (IVF) FUNDING DECISIONS: A SIMPLIFIED LIFETIME TAX CALCULATION |
|
Connolly MP1, Hoorens S2, Gallo F2, Ledger W3 |
|
1Ferring International Center, Saint-Prex, Switzerland, 2RAND Europe, Cambridge, UK, 3University of Sheffield, Sheffield, UK |
| |
|
ES8 |
COST-EFFECTIVENESS OF DARUNAVIR/R IN HIGHLY TREATMENT-EXPERIENCED HIV/AIDS PATIENTS IN DIFFERENT EUROPEAN HEALTH CARE SETTINGS |
|
Moeremans K1, Annemans L2, Smets E3, Wyffels V4, Lothgren M5, Allegri G6 |
|
1IMS HEOR, Brussels, Belgium, 2Ghent University, Gent, Belgium, 3Johnson & Johnson Pharmaceutical Services, Inc, Beerse, Belgium, 4Janssen Cilag NV, Berchem, Belgium, 5JANSSEN-CILAG, Sollentuna, Sweden, 6TIBOTEC a division of JANSSEN-CILAG SpA Italy, Cologno Monzese, Italy |
|
|
Economics of Neurological Disease |
ND1 |
COST-EFFECTIVENESS OF INTRATHECAL BACLOFEN THERAPY VERSUS CURRENT THERAPIES IN DISABLED SPASTICITY |
|
Beresniak A1, Bensmail D2, Ward A3, Wissel J4, Motta F5, Saltuari L6, Lissens J7, Cros S7 |
|
1Data Mining International, Geneva, Switzerland, 2Raymond Poincare Hospital, Garches, France, 3University Hospital of North Staffordshire, Burslem, UK, 4Kliniken Beelit Gmbh, Beelitz, Germany, 5Ospedale dei bambini, Milano, Italy, 6LKH Hochzirl, Zirl, Austria, 7Medtronic International, Tolochenaz, Switzerland |
| |
|
ND2 |
MODELING THE COST-EFFECTIVENESS OF A NEW TREATMENT FOR MS (NATALIZUMAB) COMPARED TO CURRENT STANDARD PRACTICE IN SWEDEN |
|
Kobelt G1, Berg J2, Lindgren P2, Hillert J3 |
|
1European Health Economics, Speracedes, France, 2i3 Innovus, Stockholm, Sweden, 3Karolinska Institute, Stockholm, Sweden |
| |
|
ND3 |
MODELING TREATING MULTIPLE SCLEROSIS WITH DISEASE MODIFYING DRUGS USING DISCRETE EVENT SIMULATION |
|
Guo S1, Copur D1, Ward A1, Bennett R2, Al-Sabbah A2, Meletiche DM2, Caro JJ1 |
|
1Caro Research Institute, Concord, MA, USA, 2EMD Serono, Inc, Rockland, MA, USA |
| |
|
ND4 |
COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN IN THE TREATMENT OF POST-HERPETIC NEURALGIA IN SCOTLAND |
|
Dakin HA1, Nuijten MJC2, Poulsen Nautrup B3, Liedgens H3 |
|
1Abacus International, Bicester, Oxfordshire, UK, 2Erasmus University, Rotterdam, The Netherlands, 3Grünenthal GmbH, Aachen, Germany |
|
|
Respiratory Disease |
| |
|
RS1 |
A RETROSPECTIVE, OBSERVATIONAL STUDY COMPARING OUTCOMES OF ASTHMA TREATMENT WITH FIXED COMBINATIONS OF INHALED CORTICOSTEROID AND LONG-ACTING â2-AGONIST (ICS/LABA) IN REAL-LIFE PRACTICE |
|
Thomas M1, Von Ziegenweidt J2, Wirén A3, Ståhl E3, Price D1 |
|
1University of Aberdeen, Aberdeen, UK, 2Respiratory Research Ltd, Aberdeen, UK, 3AstraZeneca, Lund, Sweden |
| |
|
RS2 |
RESOURCE USE AND FINANCIAL IMPACT OF CRITICALLY ILL PATIENTS WITH PNEUMONIA AND RESPIRATORY FAILURE IN THE UNITED STATES |
|
Mank J1, Chalfin DB2, Caeser M1 |
|
1ALTANA Pharma AG, Konstanz, Germany, 2Analytica International, Inc, New York, NY, USA |
| |
|
RS3 |
IMPACT OF SOCIO-ECONOMIC FACTORS ON PATIENTS' KNOWLEDGE OF THEIR CONDITION, INVOLVEMENT IN TREATMENT DECISIONS AND THE SUBSEQUENT COMPLIANCE WITH THEIR TREATMENT REGIMEN |
|
Palm M1, Higgins V2, Lawson R1, Piercy J3 |
|
1Adelphi Group Products, Bollington, Cheshire, UK, 2Adelphi Group Products, New York, NY, USA, 3Adelphi Group, Bollington, UK |
| |
|
RS4 |
ASTHMA COSTS AND UTILIZATION IN A MANAGED CARE ORGANIZATION |
|
Hay JW1, Zeiger RS2, Contreras RX3, Chen W3, Quinn VP3, Seal B4, Schatz MX2 |
|
1University of Southern California, Los Angeles, CA, USA, 2Kaiser Permanente Medical Center, San Diego, CA, USA, 3Kaiser Permanente Southern California Region, Pasadena, CA, USA, 4Sanofi-Aventis, Bridgewater, NJ, USA |
| |
|
|
|